Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals (Nasdaq: PHAT), a biopharmaceutical company specializing in gastrointestinal (GI) treatments, has announced its participation in two upcoming investor conferences in September 2024:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, from September 4-6, where management will engage in one-on-one meetings.
2. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY, on September 9. Management will participate in a fireside chat at 12:00 pm ET and conduct one-on-one meetings throughout the day.
A live webcast and 90-day archived recording of the fireside chat will be available on Phathom's website in the News & Events section.
Phathom Pharmaceuticals (Nasdaq: PHAT), un'azienda biofarmaceutica specializzata in trattamenti gastrointestinali (GI), ha annunciato la sua partecipazione a due prossime conferenze per investitori nel settembre 2024:
1. La 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley a New York, NY, dal 4 al 6 settembre, dove la direzione parteciperà a incontri individuali.
2. La 26ª Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright a New York, NY, il 9 settembre. La direzione parteciperà a una chiacchierata informale alle 12:00 ET e svolgerà incontri individuali durante tutta la giornata.
Un webcast dal vivo e una registrazione archiviata di 90 giorni della chiacchierata informale saranno disponibili sul sito web di Phathom nella sezione Notizie e Eventi.
Phathom Pharmaceuticals (Nasdaq: PHAT), una compañía biofarmacéutica especializada en tratamientos gastrointestinales (GI), ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024:
1. La 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York, NY, del 4 al 6 de septiembre, donde la administración llevará a cabo reuniones individuales.
2. La 26ª Conferencia Anual Global de Inversión de H.C. Wainwright en Nueva York, NY, el 9 de septiembre. La administración participará en una charla informal a las 12:00 pm ET y realizará reuniones individuales a lo largo del día.
Una transmisión en vivo y una grabación archivada de 90 días de la charla informal estarán disponibles en el sitio web de Phathom en la sección de Noticias y Eventos.
Phathom Pharmaceuticals (Nasdaq: PHAT), 위장관(GI) 치료를 전문으로 하는 바이오제약 회사가 2024년 9월에 있을 두 가지 투자자 컨퍼런스에 참가한다고 발표했습니다:
1. 9월 4일부터 6일까지 뉴욕 NY에서 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에서 경영진이 일대일 면담을 진행합니다.
2. 9월 9일 뉴욕 NY에서 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에서 경영진이 오후 12:00 ET에 파이어사이드 채팅에 참여하고, 하루 종일 일대일 면담을 수행합니다.
파이어사이드 채팅의 실시간 웹캐스트와 90일간의 아카이브 녹화본은 Phathom의 웹사이트 뉴스 및 이벤트 섹션에서 확인할 수 있습니다.
Phathom Pharmaceuticals (Nasdaq: PHAT), une entreprise biopharmaceutique spécialisée dans les traitements gastro-intestinaux (GI), a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024 :
1. La 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley à New York, NY, du 4 au 6 septembre, au cours de laquelle la direction participera à des réunions individuelles.
2. La 26e Conférence Annuelle Mondiale sur l'Investissement de H.C. Wainwright à New York, NY, le 9 septembre. La direction participera à une discussion informelle à midi ET et mènera des réunions individuelles tout au long de la journée.
Un webinaire en direct et un enregistrement archivé de 90 jours de la discussion informelle seront disponibles sur le site web de Phathom dans la section Actualités et Événements.
Phathom Pharmaceuticals (Nasdaq: PHAT), ein biopharmazeutisches Unternehmen, das sich auf gastrointestinale (GI) Behandlungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben:
1. Die 22. jährliche globale Gesundheitskonferenz von Morgan Stanley in New York, NY, vom 4. bis 6. September, bei der das Management an persönlichen Gesprächen teilnehmen wird.
2. Die 26. jährliche globale Investorenkonferenz von H.C. Wainwright in New York, NY, am 9. September. Das Management wird um 12:00 Uhr ET an einem informellen Austausch teilnehmen und den ganzen Tag über persönliche Gespräche führen.
Ein Live-Webcast und eine 90-tägige Archivaufnahme des informellen Austauschs werden im News- und Eventbereich der Website von Phathom verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
- Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Management will participate in one-on-one meetings throughout the conference, which runs from Wednesday, September 4 to Friday, September 6, 2024.
- H.C. Wainwright 26th Annual Global Investment Conference in New York, NY. Management will participate in a fireside chat on Monday, September 9, 2024, at 12:00 pm ET and one-on-one meetings throughout the day.
To access the live webcast and archived recording of the fireside chat, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
What investor conferences will Phathom Pharmaceuticals (PHAT) attend in September 2024?
When is Phathom Pharmaceuticals' (PHAT) fireside chat at the H.C. Wainwright conference?
How can investors access Phathom Pharmaceuticals' (PHAT) fireside chat webcast?
How long will the recording of Phathom Pharmaceuticals' (PHAT) fireside chat be available?
What is Phathom Pharmaceuticals' (PHAT) focus in the biopharmaceutical industry?
